# Eric J. Small

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/eric-j-small/

## Facts

| Field | Value |
| --- | --- |
| Citations | 69,466 |
| Field | Prostate Cancer Treatment and Research |
| h-index | 121 |
| i10-index | 452 |
| Last Known Institution | University of California, San Francisco |
| OpenAlex ID | https://openalex.org/A5007578304 |
| ORCID iD | https://orcid.org/0000-0003-3191-6268 |
| Works | 1,319 |

## Researcher papers

Showing 12 of 15.

- [Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer](https://scholariq.org/papers/docetaxel-and-estramustine-compared-with-mitoxantrone-and-prednisone-for/)
- [Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy](https://scholariq.org/papers/abiraterone-in-metastatic-prostate-cancer-without-previous-chemotherapy/)
- [Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group](https://scholariq.org/papers/design-and-end-points-of-clinical-trials-for-patients-with-progressive-prostate/)
- [Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3](https://scholariq.org/papers/trial-design-and-objectives-for-castration-resistant-prostate-cancer-updated/)
- [Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/prostate-cancer-version-2-2019-nccn-clinical-practice-guidelines-in-oncology/)
- [Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group](https://scholariq.org/papers/eligibility-and-response-guidelines-for-phase-ii-clinical-trials-in-androgen/)
- [Assessment of <sup>68</sup>Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer](https://scholariq.org/papers/assessment-of-sup-68-sup-ga-psma-11-pet-accuracy-in-localizing-recurrent/)
- [Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer](https://scholariq.org/papers/genomic-hallmarks-and-structural-variation-in-metastatic-prostate-cancer/)
- [Prostate Cancer, Version 1.2016](https://scholariq.org/papers/prostate-cancer-version-1-2016/)
- [Intermittent versus Continuous Androgen Deprivation in Prostate Cancer](https://scholariq.org/papers/intermittent-versus-continuous-androgen-deprivation-in-prostate-cancer/)
- [Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019](https://scholariq.org/papers/management-of-patients-with-advanced-prostate-cancer-report-of-the-advanced/)
- [Prostate Cancer, Version 2.2014](https://scholariq.org/papers/prostate-cancer-version-2-2014/)

## Researcher topics

- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [Prostate Cancer Diagnosis and Treatment](https://scholariq.org/topics/prostate-cancer-diagnosis-and-treatment/)
- [Radiopharmaceutical Chemistry and Applications](https://scholariq.org/topics/radiopharmaceutical-chemistry-and-applications/)
- [Cancer, Lipids, and Metabolism](https://scholariq.org/topics/cancer-lipids-and-metabolism/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Researcher university

- [University of California, San Francisco](https://scholariq.org/institutions/university-of-california-san-francisco/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.